# Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy

> **NCT07711314** · PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 48 (estimated)

## Conditions studied

- Prostate Cancer (Post Prostatectomy)

## Interventions

- **DRUG:** Rezvilutamide Tablets

## Key facts

- **NCT ID:** NCT07711314
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-05
- **Final completion:** 2030-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711314, "Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*